Results 191 to 200 of about 83,254 (357)

Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs. [PDF]

J Vet Pharmacol Ther
Boerngen K, Patel Y, Pittorino M, Toutain CE.   +3 more
europepmc   +1 more source

POS0479 Steroid-sparing effect of Janus kinase inhibitors compared to TNF inhibitors in rheumatoid arthritis: preliminary analysis from a single-center Italian cohort

Gilberto Cincinelli, V. Gerli, D. Pireddu, Giorgia Trignani, Francesco Ursini, A. Varvaro, Ennio Giulio Favalli, Roberto Caporali   +7 more
openalex   +1 more source

Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116 [PDF]

Aleksandra Rzewińska, Jakub Szlęk, Damian Dąbrowski, Ewelina Juszczyk, Katarzyna Mróz, Heikki Räikkönen, Mia Sivén, Maciej Wieczorek, Przemysław Dorożyński   +8 more
openalex   +1 more source

Sphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation

VIEW, EarlyView.
This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu, Guiling Yan, Junhong Li, Yuan Yuan, Hong Zhang, Yuchao Zhong, Yuanyuan Peng, Wenjia Zhang, Xiaoyan Su, Changchun Niu, Yang Luo   +10 more
wiley   +1 more source

Progression of mycosis fungoides in a patient receiving a Janus kinase inhibitor. [PDF]

JAAD Case Rep
Stankiewicz JM, Kersten JM, Merkus VA, de Haan S, Jansen PM, Vermeer MH, Ottevanger R.   +6 more
europepmc   +1 more source

Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib [PDF]

Justin Arnall, Lindsey Lyle, Donald C. Moore   +2 more
openalex   +1 more source

Refractory Lichen Amyloidosis Coexisting With Atopic Dermatitis Responsive to Sequential Janus Kinase Inhibitor Therapy: Upadacitinib Followed by Abrocitinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
Yu‐Ting Tsai, Jui Lan, Shang‐Hung Lin   +2 more
wiley   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki, Ryo Saito, Kenta Suzuki, Daisuke Watanabe, Masako Minami‐Hori, Hirofumi Kamada, Hiroo Amano, Akihiko Uchiyama, Sei‐ichiro Motegi, Machiko Kamura, Kazunari Sugita, Noriko Kubota, Toshifumi Nomura, Maki Ozawa, Toshiya Takahashi, Takashi Yamakita, Kazumitsu Sugiura, Tetsuharu Ikegami, Ken Igawa, Yuka Kimura, Yoko Kataoka, Ryoichi Kamide, Masakazu Takahashi, Akio Tanaka, Mariko Sugawara‐Mikami   +24 more
wiley   +1 more source

Janus Kinase Inhibitor: A Possible Cause of Hyperammonemic Encephalopathy? [PDF]

J Clin Neurol
Park JH, Kim DH.
europepmc   +1 more source

P190 An international modified Delphi study to understand clinical opinion on current and potential future use of Janus kinase inhibitors in rheumatic and musculoskeletal diseases: global results [PDF]

Anna Barkaway, Philip J. Mease, Robert J. Moots, Mwidimi Ndosi, Zoe Rutter‐Locher, Michael McLean   +5 more
openalex   +1 more source